Zai Lab Limited NASDAQ:ZLAB

Founder-led company

Zai Lab Limited stock price today

$35.55
+8.93
+33.6%
Financial Health
0
1
2
3
4
5
6
7
8
9

Zai Lab Limited stock price monthly change

+47.51%
month

Zai Lab Limited stock price quarterly change

+47.51%
quarter

Zai Lab Limited stock price yearly change

+2.15%
year

Zai Lab Limited key metrics

Market Cap
2.89B
Enterprise value
2.54B
P/E
-8.19
EV/Sales
11.84
EV/EBITDA
-5.92
Price/Sales
16.44
Price/Book
3.38
PEG ratio
-0.16
EPS
-3.49
Revenue
291.07M
EBITDA
-320.71M
Income
-338.94M
Revenue Q/Q
38.77%
Revenue Y/Y
25.94%
Profit margin
-206.14%
Oper. margin
-188.04%
Gross margin
65.58%
EBIT margin
-188.04%
EBITDA margin
-110.18%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Zai Lab Limited stock price history

Zai Lab Limited stock forecast

Zai Lab Limited financial statements

Zai Lab Limited (NASDAQ:ZLAB): Profit margin
Jun 2023 68.86M -120.89M -175.56%
Sep 2023 69.22M -69.15M -99.89%
Dec 2023 65.83M -95.42M -144.96%
Mar 2024 87.14M -53.47M -61.36%
Zai Lab Limited (NASDAQ:ZLAB): Analyst Estimates
2025 596.51M -157.33M -26.38%
2026 942.82M 70.69M 7.5%
2027 1.40B 143.17M 10.21%
2028 1.77B 327.17M 18.39%
  • Analysts Price target

  • Financials & Ratios estimates

Zai Lab Limited (NASDAQ:ZLAB): Debt to assets
Jun 2023 1106373000 174.05M 15.73%
Sep 2023 1043694000 162.71M 15.59%
Dec 2023 1036295000 240.17M 23.18%
Mar 2024 988437000 226.26M 22.89%
Zai Lab Limited (NASDAQ:ZLAB): Cash Flow
Jun 2023 -58.70M 42.70M -1.49M
Sep 2023 -55.27M -13.98M -1.44M
Dec 2023 -14.91M 14.45M 393K
Mar 2024 -90.10M 3.29M 47.54M

Zai Lab Limited alternative data

Zai Lab Limited (NASDAQ:ZLAB): Employee count
Aug 2023 2,036
Sep 2023 2,036
Oct 2023 2,036
Nov 2023 2,036
Dec 2023 2,036
Jan 2024 2,036
Feb 2024 2,036
Mar 2024 2,175
Apr 2024 2,175
May 2024 2,175
Jun 2024 2,175
Jul 2024 2,175

Zai Lab Limited other data

65.45% -2.60%
of ZLAB is owned by hedge funds
60.86M -3.80M
shares is hold by hedge funds

Zai Lab Limited (NASDAQ:ZLAB): Insider trades (number of shares)
Period Buy Sel
Nov 2023 5000 165
Dec 2023 4000 0
Jan 2024 0 37349
Mar 2024 3000 12544
Apr 2024 0 17098
May 2024 3000 10000
Jun 2024 0 38586
Jul 2024 0 17410
Transaction Date Insider Security Shares Price per share Total value Source
Sale
LIS WILLIAM director
American Depositary Shares 10,297 $17.31 $178,282
Sale
LIS WILLIAM director
American Depositary Shares 100 $18.04 $1,804
Sale
DU YING director, officer.. American Depositary Shares 7,013 $17.48 $122,573
Option
DU YING director, officer.. American Depositary Shares 17,970 N/A N/A
Option
DU YING director, officer.. Restricted Share Units 17,970 N/A N/A
Sale
REINHART HARALD officer: See Remarks
American Depositary Shares 7,431 $17.9 $133,022
Sale
DU YING director, officer.. American Depositary Shares 23,939 $17.9 $428,532
Sale
EDMONDSON FRAZOR TITUS III officer: Chief Le.. American Depositary Shares 5,062 $17.9 $90,615
Sale
CHEN YAJING officer: Chief Financial Officer
American Depositary Shares 2,154 $17.9 $38,559
Option
REINHART HARALD officer: See Remarks
American Depositary Shares 18,250 N/A N/A
Thursday, 26 December 2024
seekingalpha.com
Tuesday, 24 December 2024
zacks.com
Thursday, 12 December 2024
businesswire.com
Monday, 2 December 2024
businesswire.com
Wednesday, 27 November 2024
businesswire.com
Thursday, 21 November 2024
businesswire.com
Monday, 18 November 2024
businesswire.com
Thursday, 14 November 2024
businesswire.com
Wednesday, 13 November 2024
businesswire.com
Tuesday, 12 November 2024
zacks.com
seekingalpha.com
businesswire.com
Monday, 11 November 2024
businesswire.com
Tuesday, 29 October 2024
businesswire.com
Friday, 25 October 2024
zacks.com
Thursday, 24 October 2024
businesswire.com
Friday, 18 October 2024
businesswire.com
Thursday, 17 October 2024
businesswire.com
Wednesday, 16 October 2024
businesswire.com
Wednesday, 9 October 2024
businesswire.com
Friday, 27 September 2024
zacks.com
Wednesday, 25 September 2024
seekingalpha.com
Tuesday, 17 September 2024
businesswire.com
Friday, 26 July 2024
investorplace.com
Tuesday, 16 July 2024
businesswire.com
Wednesday, 10 July 2024
zacks.com
zacks.com
businesswire.com
businesswire.com
Tuesday, 11 June 2024
businesswire.com
  • What's the price of Zai Lab Limited stock today?

    One share of Zai Lab Limited stock can currently be purchased for approximately $35.55.

  • When is Zai Lab Limited's next earnings date?

    Unfortunately, Zai Lab Limited's (ZLAB) next earnings date is currently unknown.

  • Does Zai Lab Limited pay dividends?

    No, Zai Lab Limited does not pay dividends.

  • How much money does Zai Lab Limited make?

    Zai Lab Limited has a market capitalization of 2.89B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 24.03% to 266.72M US dollars.

  • What is Zai Lab Limited's stock symbol?

    Zai Lab Limited is traded on the NASDAQ under the ticker symbol "ZLAB".

  • What is Zai Lab Limited's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Zai Lab Limited?

    Shares of Zai Lab Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Zai Lab Limited's key executives?

    Zai Lab Limited's management team includes the following people:

    • Dr. Ying Du Founder, Chairperson & Chief Executive Officer(age: 59, pay: $1,380,000)
    • Mr. Frazor Titus Edmondson III Chief Legal Officer & Corporation Sec.(age: 59, pay: $707,300)
    • Mr. Tao Fu Chief Strategy Officer(age: 53, pay: $649,770)
    • Mr. Ki Chul Cho Chief Financial Officer(age: 47, pay: $624,960)
    • Dr. Alan Bart Sandler M.D. Pres & Head of Global Devel. in Oncology(age: 68, pay: $545,000)
  • Is Zai Lab Limited founder-led company?

    Yes, Zai Lab Limited is a company led by its founder Dr. Ying Du.

  • How many employees does Zai Lab Limited have?

    As Jul 2024, Zai Lab Limited employs 2,175 workers.

  • When Zai Lab Limited went public?

    Zai Lab Limited is publicly traded company for more then 7 years since IPO on 20 Sep 2017.

  • What is Zai Lab Limited's official website?

    The official website for Zai Lab Limited is zailaboratory.com.

  • How can i contact Zai Lab Limited?

    Zai Lab Limited can be reached via phone at +86 21 6163 2588.

Zai Lab Limited company profile:

Zai Lab Limited

zailaboratory.com
Exchange:

NASDAQ

Full time employees:

2,175

Industry:

Biotechnology

Sector:

Healthcare

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.

Jinchuang Plaza
Shanghai, 201210

CIK: 0001704292
ISIN: US98887Q1040
CUSIP: 98887Q104